

**Biowaiver Assessment Report for**

**Oral Suspensions**

**Bioequivalence Working Group for Generics**

|  |  |  |  |
| --- | --- | --- | --- |
| Version | Description of Change | Author | Effective Date |
| v 1 | Original publication | BEWGG | 7 Nov 2024 |
|  |  |  |  |
|  |  |  |  |

**Disclaimer**

This document reflects the views of subject matter experts participating in the IPRP Bioequivalence Working Group for Generics (BEWGG) and should not be construed to represent the official view of any given regulatory authority participating in the IPRP.

**Biowaiver Assessment Report for**

**Oral Suspensions**

**<Proposed proprietary name>**

**<API> <Product strength(s)> <Product dosage form>**

**<Application/Dossier reference number>**

**Applicant: <Name of the Applicant>**

Table of Contents

1 GLOSSARY / ABBREVIATIONS 4

2 SUMMARY: REQUIREMENTS and OUTCOMES 5

3 ASSESSMENT OF THE BIOWAIVER 6

3.1 Application objective 6

3.2 Comparator product 6

3.3 Nature of the dosage form 6

3.4 Qualitative and quantitative composition (Proposed Product vs Comparator Product) 6

3.5 Physicochemical properties (Proposed Product vs Comparator Product) 7

3.6 In vitro drug release tests (Proposed Product vs Comparator Product) 8

4 LIST OF OUTSTANDING ISSUES / DEFICIENCIES / PROPOSED QUESTIONS 9

5 CONCLUSIONS AND RECOMMENDATIONS 9

# GLOSSARY / ABBREVIATIONS

**API, Drug** Active pharmaceutical ingredient / Drug substance

**Drug product** Pharmaceutical product / Medicinal product / Medicine/ Final product

# SUMMARY: REQUIREMENTS and OUTCOMES

|  |  |
| --- | --- |
| **Requirements** | **Outcome** |
| **Dosage form** | Suspension |
| **Route of Administration** | Oral |
| **Qualitative composition of the excipients compared to the Comparator Product** | Sufficiently similar / Unacceptable differences |
| **Quantitative composition of the excipients compared to the Comparator Product** | Sufficiently similar / Unacceptable differences |
| **Physicochemical properties** | Sufficiently similar / Unacceptable differences |
| **Therapeutic index** | Non-narrow / Narrow |
| **Conclusion** | Approvable / Non-approvable |

|  |
| --- |
| *Note:*  *The waiver requirements described here also apply to powders and granules for oral suspensions that are administered as suspensions after reconstitution.* |

# ASSESSMENT OF THE BIOWAIVER

## Application objective

Clearly state the regulatory/scientific basis for the biowaiver request for the proposed product. In general, biowaivers for systemically acting oral suspensions are not accepted. However, biowaivers may be considered for locally-acting oral suspensions without systemic absorption/action.

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

## Comparator product

State the relevant details of the comparator product for the application, e.g. product name, dosage form, strengths, marketing authorisation holder.

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

## Nature of the dosage form

Clearly state the nature of the proposed dosage form and state if it is the same dosage form as the Comparator Product. If not, please justify.

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

## Qualitative and quantitative composition (Proposed Product vs Comparator Product)

A listing of the excipients in the proposed product and comparator product and their quantities should be provided. If there are differences in excipients (e.g. hydration form, polymorphism, viscosity grade), these should be clearly listed

The following table can be replicated for each product strength, if needed.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Component** | **Function** | **Proposed Product**  **Composition (unit)** | **Comparator Product**  **Composition (unit)** | **% difference**  **(test/comparator)** | **Maximum amount per dose or MDD\*** | **IID limit\*** |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

\*if there are qualitative/quantitative differences in any component; MDD: Maximum daily dose; IID: Inactive Ingredient Database

☐ Yes ☐ No The qualitative composition of the proposed product and the comparator product is the same.

In general, the excipient composition should be qualitatively the same between the proposed product and the comparator product for a biowaiver to be considered.

If there are qualitative differences in the compositions, any potential impact on bioavailability should be highlighted.

|  |
| --- |
| ***Assessor’s comment:*** *< describe and explain if differences are acceptable>* |

☐ Yes ☐ No The quantitative composition of the proposed product and the comparator product is the same.

In general, the quantitative composition should be quantitatively the same between the proposed product and the comparator product for a biowaiver to be considered.

If there are quantitative differences in the compositions, any potential impact on pharmacokinetics/bioavailability should be highlighted.

|  |
| --- |
| ***Assessor’s comment:*** *< describe and explain if differences are acceptable.>* |

## Physicochemical properties (Proposed Product vs Comparator Product)

Physicochemical comparability should be discussed in each respective section below.

Details on the expected data should be provided, e.g. batch numbers, number of batches/samples, any statistical analysis results (such as mean, %CV).

Add further parameters as required. Not all parameters may be required in certain markets.

1. **pH**

XX

|  |  |  |  |
| --- | --- | --- | --- |
| **Product** | **Observed result** | **Mean (%CV)** | **Mean Ratio (Tolerance)** |
| Comparator | Experiment 1  Experiment 2  Experiment 3 |  |  |
| Test | Experiment 1  Experiment 2  Experiment 3 |  |

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

1. **Viscosity**

XX

*The table in A. pH can be replicated in this and the following sections as needed.*

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

1. **Particle size distribution**

XX

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

1. **Crystallographic structure / Polymorphic form**

XX

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

1. **Dispersion time**

XX

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

1. **Other physicochemical properties**

XX

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

## In vitro drug release tests (Proposed Product vs Comparator Product)

The methodology used for *in vitro* drug release testing should be described in sufficient detail.

Details on the expected data should be provided, e.g. number of batches/samples, any statistical analysis results (such as mean, %CV), f2 or other suitable method for release data comparison.

1. **In vitro dissolution profiles at pH 1.2 to 6.8**

XX

|  |
| --- |
| ***Assessor’s comments:*** *<Please comment here>* |

# LIST OF OUTSTANDING ISSUES / DEFICIENCIES / PROPOSED QUESTIONS

|  |
| --- |
|  |

# CONCLUSIONS AND RECOMMENDATIONS

|  |
| --- |
|  |